

sub  
B1  
AT  
COT

73. (New) The method of claim 55, wherein said reverse transcriptase is selected from the group consisting of avian myeloblastosis virus (AMV) reverse transcriptase, Moloney-murine-leukemia virus (MMuLV) reverse transcriptase, and Rous Sacroma Virus (RSV) reverse transcriptase.

74. (New) The method of claim 43, wherein said population of cRNA is produced using *in vitro* transcription.

75. (New) The method of claim 57, wherein said first strand cDNA is synthesized using a polymerase that has reverse transcriptase activity

sub  
B1

76. (New) The method of claim 43, wherein said second strand cDNA is synthesized using a DNA polymerase.

77. (New) The method of claim 57 wherein said second strand cDNA is synthesized using a DNA polymerase.

---

**IN THE SPECIFICATION**

At page 4, after line 6, add the following new paragraph:

A2

In Step 1 100 pmol of oligo dT-T7 and reverse transcriptase are used. In Step 2 the RNA/DNA complex is heated to 95°C for 5 minutes to denature and separate the complex. In Step 3 100 µg of random hexamer, Klenow, and T4 DNA Polymerase are incubated for 2 hours at 37°C. In Step 4 T7 RNA Polymerase and biotinylated CTP/UTP are added to accomplish *in vitro* transcription.

---

U.S. Application No.: 09/738,892  
Page 6


Attorney Dkt. 003848.00059

November 8, 2001

Banner & Witcoff, LTD.  
Eleventh Floor  
1001 G Street, N.W.  
Washington, D.C. 2001  
(202) 508-9100

Respectfully submitted,

By:

A handwritten signature in black ink, appearing to read "Sarah A. Kagan", written over a horizontal line.

Sarah A. Kagan  
Registration No. 32,141